PREVENT Risk Stratification for Intensive Blood Pressure Intervention and Life Expectancy in Rural China: A Post Hoc Analysis of the China Rural Hypertension Control Project

BACKGROUND: The 2025 American Heart Association/American College of Cardiology guideline adopted the Predicting Risk of Cardiovascular Disease Events (PREVENT) equations to guide antihypertensive treatment, but whether PREVENT risk groups identify patients who benefit more from intensive blood pressure (BP) control is uncertain. We evaluated intensive BP control across PREVENT risk groups in the China Rural Hypertension Control Project. METHODS: We analyzed 21 872 hypertensive adults from 326 Chinese villages. Participants received intensive BP control (target <130/80 mm Hg) or usual care and were classified as low risk (<5%), borderline risk (5.0%-7.4%), intermediate risk (7.5%-19.9%), or high risk (≥20%). The primary outcome was a composite of major cardiovascular events (myocardial infarction, stroke, heart failure, or cardiovascular death). Safety, net benefit, and life expectancy were assessed. RESULTS: Over a median of 3.02 years, intensive BP control was associated with lower cardiovascular risk in the low-risk (hazard ratio, 0.53 [95% CI, 0.29-0.97]), intermediate-risk (hazard ratio, 0.58 [95% CI, 0.49-0.69]), and high-risk groups (hazard ratio, 0.60 [95% CI, 0.47-0.77]), but not the borderline-risk group (hazard ratio, 0.80 [95% CI, 0.51-1.26]). No significant treatment-by-risk interaction was observed. Adverse events increased mainly in intermediate- and high-risk groups. Net benefit was favorable across all groups and greatest in the high-risk group. At 45 years of age, estimated life expectancy gains were 0.94 years overall, 0.71 years in the intermediate-risk group, and 1.26 years in the high-risk group. CONCLUSIONS: Intensive BP control was associated with lower cardiovascular risk in 3 PREVENT risk groups, with favorable net benefit across all groups. Absolute benefit and estimated life expectancy gains were greatest among high-risk participants. PREVENT risk stratification may inform intensive BP control in community-based hypertensive populations.

Authors

Institutions

Publication Details

Journal
Hypertension
Published
2026-11-18
DOI
https://doi.org/10.1161/hypertensionaha.126.27624
Primary Topic
Blood Pressure and Hypertension Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

PREVENT Risk Stratification for Intensive Blood Pressure Intervention and Life Expectancy in Rural China: A Post Hoc Analysis of the China Rural Hypertension Control Project

Caiyu Zhang, Xiaoqiong Jiang, Nanxiang Ouyang, 张新刚 et al.
6 links
Hypertension
Blood Pressure and Hypertension Studies
article

PREVENT Risk Stratification for Intensive Blood Pressure Intervention and Life Expectancy in Rural China: A Post Hoc Analysis of the China Rural Hypertension Control Project

Caiyu Zhang, Xiaoqiong Jiang, Nanxiang Ouyang, 张新刚, Jiaqi Xu, Wenhang Li, Boquan Wu, Yingxian Sun, Chang Wang, Xiaofan Guo, Yangzhi Yin, Guangxiao Li, Xiangyu Tan, Chenhua He, Xiaoxuan Tian, Hongtai Li, Yifei Chen, Jie Chen, Wei Miao, Ning Ye
article en

Abstract

BACKGROUND: The 2025 American Heart Association/American College of Cardiology guideline adopted the Predicting Risk of Cardiovascular Disease Events (PREVENT) equations to guide antihypertensive treatment, but whether PREVENT risk groups identify patients who benefit more from intensive blood pressure (BP) control is uncertain. We evaluated intensive BP control across PREVENT risk groups in the China Rural Hypertension Control Project. METHODS: We analyzed 21 872 hypertensive adults from 326 Chinese villages. Participants received intensive BP control (target <130/80 mm Hg) or usual care and were classified as low risk (<5%), borderline risk (5.0%-7.4%), intermediate risk (7.5%-19.9%), or high risk (≥20%). The primary outcome was a composite of major cardiovascular events (myocardial infarction, stroke, heart failure, or cardiovascular death). Safety, net benefit, and life expectancy were assessed. RESULTS: Over a median of 3.02 years, intensive BP control was associated with lower cardiovascular risk in the low-risk (hazard ratio, 0.53 [95% CI, 0.29-0.97]), intermediate-risk (hazard ratio, 0.58 [95% CI, 0.49-0.69]), and high-risk groups (hazard ratio, 0.60 [95% CI, 0.47-0.77]), but not the borderline-risk group (hazard ratio, 0.80 [95% CI, 0.51-1.26]). No significant treatment-by-risk interaction was observed. Adverse events increased mainly in intermediate- and high-risk groups. Net benefit was favorable across all groups and greatest in the high-risk group. At 45 years of age, estimated life expectancy gains were 0.94 years overall, 0.71 years in the intermediate-risk group, and 1.26 years in the high-risk group. CONCLUSIONS: Intensive BP control was associated with lower cardiovascular risk in 3 PREVENT risk groups, with favorable net benefit across all groups. Absolute benefit and estimated life expectancy gains were greatest among high-risk participants. PREVENT risk stratification may inform intensive BP control in community-based hypertensive populations.

Hypertension
First Hospital of China Medical University (CN), China Medical University (CN)
Good health and well-being
Blood Pressure and Hypertension Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon